The aggresome pathway as a target for therapy in hematologic malignancies

Tiffany Simms-Waldrip, Agustin Rodriguez-Gonzalez, Tara Lin, Alan K. Ikeda, Cecilia Fu, Kathleen M. Sakamoto

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Misfolded or unfolded proteins are often refolded with the help of chaperones or degraded by the 26S proteasome. An alternative fate of these proteins is the aggresome pathway. The microtubule-organizing center (MTOC) transports unfolded proteins to lysosomes and are degraded through autophagy. Histone deacetylase 6 (HDAC6) deacetylates α-tubulin, which is thought to be a component of the MTOC. Recently, two small molecule inhibitors of the aggresome pathway and HDAC6 have been described. One inhibitor, tubacin, prevents deacetylation of α-tubulin and produces accumulation of polyubiquitinated proteins and apoptosis. Tubacin acts synergistically with the proteasome inhibitor, bortezomib, to induce cytotoxicity in one type of hematologic malignancy, multiple myeloma. The other, LBH589, is a pan HDAC inhibitor and hydroxamic acid derivative that induces apoptosis of multiple myeloma cells resistant to conventional therapies. In this review, we summarize recent reports on targeting the aggresome pathway and HDAC6 in hematologic malignancies.

Original languageEnglish (US)
Pages (from-to)283-286
Number of pages4
JournalMolecular Genetics and Metabolism
Volume94
Issue number3
DOIs
StatePublished - Jul 2008

Fingerprint

Histone Deacetylases
Hematologic Neoplasms
Microtubule-Organizing Center
Tubulin
Multiple Myeloma
Protein Refolding
Apoptosis
Hydroxamic Acids
Proteins
Proteasome Inhibitors
Histone Deacetylase Inhibitors
Autophagy
Cytotoxicity
Lysosomes
Carrier Proteins
Therapeutics
Derivatives
Molecules
tubacin

Keywords

  • α-Tubulin
  • Aggresomes
  • Apoptosis
  • HDAC6
  • Multiple myeloma
  • Protein degradation

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Endocrinology, Diabetes and Metabolism

Cite this

The aggresome pathway as a target for therapy in hematologic malignancies. / Simms-Waldrip, Tiffany; Rodriguez-Gonzalez, Agustin; Lin, Tara; Ikeda, Alan K.; Fu, Cecilia; Sakamoto, Kathleen M.

In: Molecular Genetics and Metabolism, Vol. 94, No. 3, 07.2008, p. 283-286.

Research output: Contribution to journalArticle

Simms-Waldrip, Tiffany ; Rodriguez-Gonzalez, Agustin ; Lin, Tara ; Ikeda, Alan K. ; Fu, Cecilia ; Sakamoto, Kathleen M. / The aggresome pathway as a target for therapy in hematologic malignancies. In: Molecular Genetics and Metabolism. 2008 ; Vol. 94, No. 3. pp. 283-286.
@article{5eeef52dcced4e8c90f9c0bb4b172226,
title = "The aggresome pathway as a target for therapy in hematologic malignancies",
abstract = "Misfolded or unfolded proteins are often refolded with the help of chaperones or degraded by the 26S proteasome. An alternative fate of these proteins is the aggresome pathway. The microtubule-organizing center (MTOC) transports unfolded proteins to lysosomes and are degraded through autophagy. Histone deacetylase 6 (HDAC6) deacetylates α-tubulin, which is thought to be a component of the MTOC. Recently, two small molecule inhibitors of the aggresome pathway and HDAC6 have been described. One inhibitor, tubacin, prevents deacetylation of α-tubulin and produces accumulation of polyubiquitinated proteins and apoptosis. Tubacin acts synergistically with the proteasome inhibitor, bortezomib, to induce cytotoxicity in one type of hematologic malignancy, multiple myeloma. The other, LBH589, is a pan HDAC inhibitor and hydroxamic acid derivative that induces apoptosis of multiple myeloma cells resistant to conventional therapies. In this review, we summarize recent reports on targeting the aggresome pathway and HDAC6 in hematologic malignancies.",
keywords = "α-Tubulin, Aggresomes, Apoptosis, HDAC6, Multiple myeloma, Protein degradation",
author = "Tiffany Simms-Waldrip and Agustin Rodriguez-Gonzalez and Tara Lin and Ikeda, {Alan K.} and Cecilia Fu and Sakamoto, {Kathleen M.}",
year = "2008",
month = "7",
doi = "10.1016/j.ymgme.2008.03.012",
language = "English (US)",
volume = "94",
pages = "283--286",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - The aggresome pathway as a target for therapy in hematologic malignancies

AU - Simms-Waldrip, Tiffany

AU - Rodriguez-Gonzalez, Agustin

AU - Lin, Tara

AU - Ikeda, Alan K.

AU - Fu, Cecilia

AU - Sakamoto, Kathleen M.

PY - 2008/7

Y1 - 2008/7

N2 - Misfolded or unfolded proteins are often refolded with the help of chaperones or degraded by the 26S proteasome. An alternative fate of these proteins is the aggresome pathway. The microtubule-organizing center (MTOC) transports unfolded proteins to lysosomes and are degraded through autophagy. Histone deacetylase 6 (HDAC6) deacetylates α-tubulin, which is thought to be a component of the MTOC. Recently, two small molecule inhibitors of the aggresome pathway and HDAC6 have been described. One inhibitor, tubacin, prevents deacetylation of α-tubulin and produces accumulation of polyubiquitinated proteins and apoptosis. Tubacin acts synergistically with the proteasome inhibitor, bortezomib, to induce cytotoxicity in one type of hematologic malignancy, multiple myeloma. The other, LBH589, is a pan HDAC inhibitor and hydroxamic acid derivative that induces apoptosis of multiple myeloma cells resistant to conventional therapies. In this review, we summarize recent reports on targeting the aggresome pathway and HDAC6 in hematologic malignancies.

AB - Misfolded or unfolded proteins are often refolded with the help of chaperones or degraded by the 26S proteasome. An alternative fate of these proteins is the aggresome pathway. The microtubule-organizing center (MTOC) transports unfolded proteins to lysosomes and are degraded through autophagy. Histone deacetylase 6 (HDAC6) deacetylates α-tubulin, which is thought to be a component of the MTOC. Recently, two small molecule inhibitors of the aggresome pathway and HDAC6 have been described. One inhibitor, tubacin, prevents deacetylation of α-tubulin and produces accumulation of polyubiquitinated proteins and apoptosis. Tubacin acts synergistically with the proteasome inhibitor, bortezomib, to induce cytotoxicity in one type of hematologic malignancy, multiple myeloma. The other, LBH589, is a pan HDAC inhibitor and hydroxamic acid derivative that induces apoptosis of multiple myeloma cells resistant to conventional therapies. In this review, we summarize recent reports on targeting the aggresome pathway and HDAC6 in hematologic malignancies.

KW - α-Tubulin

KW - Aggresomes

KW - Apoptosis

KW - HDAC6

KW - Multiple myeloma

KW - Protein degradation

UR - http://www.scopus.com/inward/record.url?scp=44949234487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44949234487&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2008.03.012

DO - 10.1016/j.ymgme.2008.03.012

M3 - Article

C2 - 18472289

AN - SCOPUS:44949234487

VL - 94

SP - 283

EP - 286

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 3

ER -